hypertensive patients with renal disease
Conditions
Interventions
cilnidine 10-20mg/day in combination with angiotensin receptor blocker (ARB) or angiotensin converting enzyme (ACE)inhibitor
amlodipine 5-10 mg/day in combination with ARB or ACEinhibitor
Sponsors
University of Tokyo Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Urinary protein is 300mg/gCr and above 2. Serum creatinine is 3.0 mg/dl and below 3. Blood pressure is 130/85 mmHg and above 4. Patients who give a written informed consent 5. Patients who have been administered angiotensin receptor blocker (ABR) or angiotensin converting enzyme (ACE) inhibitor during 2-3 months and above
Exclusion criteria
Exclusion criteria: 1. Hypertensive emergency 2. Severe heart failure, severe arrhythmia, angina, myocardial infarction within 6 months of onset 3. Stroke within 6 months of onset 4. Severe diabetes mellitus 5. Prengnancy and possible pregnancy 6. History of severe side effect of calcium channel blocker, ARB, or ACE inhibitor 7. Patients who are treateing with cilnidipine or amlodipine 8. Patinets who are inadequate to entry this study by physicians in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary protein as protein/creatinine ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular death Cardiovascular event | — |
Countries
Japan
Contacts
Public ContactKatsuyuki Ando
University of Tokyo Graduate School of Medicine Molecular and Cardiovascular Metabolism
Outcome results
None listed